Background After thrombolytic therapy, long-term patency of the infarct-related artery may reduce arrhythmias, limit ventricular dilatation, and provide collaterals to another infarct zone if further infarction occurs. However, independent long-term prognostic value of infarct artery patency has not been shown.
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Methods and Results We followed 312 patients with first myocardial infarction treated <4 hours after pain onset with thrombolysis (streptokinase [n=188] or recombinant tissuetype plasminogen activator [n=124] ). At 28±+11 days, cardiac catheterization was performed. Flow of the infarct-related artery was assessed by the TIMI scoring system, and a scoring system relating coronary stenoses and flow to the amount of myocardium supplied was also used. Follow-up was for 39+13 months. Cardiac death occurred in 5.8% of patients, and there were two noncardiac deaths. Revascularization was performed in 11 .5% of patients. On univariate and multivariate analysis, ventricular function (ejection fraction, P=.006 and .02, or end-systolic volume index, P=.01 and .06) was the most T hrombolytic therapy has substantially reduced early1-4 and long-term mortality5-13 after acute myocardial infarction. Before the thrombolytic era, it was established that left ventricular size'4 and function,'5 best represented by left ventricular endsystolic volume, was the most important prognostic factor after recovery from infarction.'4 The major mechanism by which thrombolytic therapy improves longterm survival appears to be preservation of left ventricular function.'0"13"6 Evidence is accumulating, however, that reestablishing perfusion of a coronary artery may have prognostic benefits independent of myocardial salvage. '7-21 Possible mechanisms include reduction of ventricular remodeling,17-'9 reducing the incidence of arrhythmias,2021 and providing collaterals to other territories in the event of future coronary artery occlusion. The aim of this study was to identify clinical and angiographic features that might predict long-term survival after thrombolytic therapy, with particular atten-tion to infarct artery patency and left ventricular function.
Methods

Study Population
Patients with first myocardial infarctions enrolled in two thrombolytic trials22'23 were followed from the time of cardiac catheterization 28±11 days after infarction. Both trials evaluated left ventricular function. The first trial showed that streptokinase was better than placebo,22 and the second showed that tissue-type plasminogen activator (t-PA) was equivalent to streptokinase.23 Patients were c70 years old and were enrolled <4 hours after the onset of chest pain lasting at least 30 minutes and associated with ST-segment elevation in at least two leads on the ECG. ST elevation of 1 mm or more in the limb leads or V4 through V6 and 2 mm or more in leads V, through V3 was required. Patients were excluded from the study if they had a previous stroke, confirmed peptic ulcer in the previous 12 
Follow-up
Patients were followed up every 3 to 6 months for the first 12 months. Patients received advice about a low-fat diet (25% to 30% of total calories), and those who were overweight were advised to achieve ideal body weight. Most who continued to have cholesterol levels >6.5 mmol/L were begun on lipidlowering medication. Patients were advised to stop smoking and to exercise regularly.
Medications were recorded at discharge after cardiac catheterization. Smoking was recorded if patients smoked for at least 1 year of follow-up. At 3 to 4 weeks, patients underwent (reflecting the amount of myocardium supplied by arteries with significant stenoses but not totally occluded) was not associated with long-term mortality.
The ejection fraction was the same for patients treated at less than the median time of 2.5 hours (57.5±12%) as for patients treated later than 2.5 hours (57+11%). Patency of the infarct-related artery was 75% in the early group and 65% in the later group (P=.04). On multivariate analysis, the best Cox proportionalhazards models included both a measure of left ventricular function (ejection fraction or end-systolic volume index) and a measure representing coronary artery occlusion (occlusion score), followed by exercise duration. Significance levels and /-coefficients for the various models are shown in Table 4 . Occlusion score (either TIMI 3 versus TIMI 0, 1, and 2 flow or TIMI 2 and 3 versus TIMI 0 and 1 flow) was an independent prognostic factor when added to either measure of left ventricular function. As in the univariate analysis, TIMI flow alone was less associated with long-term outcome. The risk ratio for TIMI 3 versus TIMI 0, 1, and 2 flow was 0.5 (95% confidence interval, 0.18 to 1.39).
1 is occlusion with some penetration; TIMI 0 is occlusion.
Comparison of Patients With Patent Versus Occluded Infarct-Related Arteries
For patients with occluded arteries, treadmill exercise duration was the only prognostic factor, whereas for the subgroup of patients with patent infarct-related arteries, /3-blocker therapy was important. The Figure shows the importance of patent infarct-related arteries in relation to ejection fraction. For patients with ejection fractions 250%, an occluded artery (TIMI 3 versus TIMI 0, 1, and 2 flow) was a significant adverse factor only when it supplied more than four myocardial units, ie, approximately 25% of the left ventricle, whereas when the ejection fraction was <50%, an occluded coronary artery was an adverse prognostic factor whatever its myocardial distribution. This was also evident for patients with ejection fractions <40%.
Discussion
This study confirms left ventricular function as an important long-term prognostic factor in the thrombolytic era and shows that an occluded infarct-related 
Yes 4 5 Actuarial survival curves for patients with ejection fractions .50% (top left), <50% (bottom left), and <40% (above). For each ejection fraction division, survival is shown according to three divisions of the occlusion score. -denotes patent arteries with an occlusion score of 0, ---denotes occluded arteries with occlusion scores >0 to 4.0 supplying up to 25% of the left ventricle, and --denotes occlusion scores >4.0 to 8.0 with occluded arteries supplying >25% of the left ventricle.
Years artery is also an independent predictor. These two factors are intimately related, since early and sustained patency results in myocardial salvage and preservation of left ventricular function. 16 In the prethrombolytic era, end-systolic volume was shown to be a more important prognostic factor than ejection fraction, and end-systolic volume added additional prognostic information when the ejection fraction was <50%.'4 Since a smaller proportion of thrombolytic-treated patients have low ejection fractions, it is more difficult for thrombolytic trials to have the statistical power to prove that end-systolic volume provides additional prognostic information to ejection fraction. In the present study, ejection fraction and end-systolic volume appeared to have similar prognostic importance.
The recent GUSTO trial has shown the importance of 90-minute patency for short-term survival.28 Before the present study, however, the independent long-term prognostic importance of coronary artery patency after thrombolysis, when left ventricular function is also taken into account, had not been firmly established. In the prethrombolytic era, several trials had shown on retrospective analysis in selected patients that patency appeared to be important (Table 5 ).29-32 Several trials have shown univariate prognostic importance of infarct artery patency after thrombolytic therapy.9'13,33-35 Many of these trials were confounded by high rates of coronary artery revascularization,33,34 making it difficult to determine whether patency of the infarct-related artery or revascularization is more important in determining long-term prognosis. Furthermore, in these studies, not all patients had left ventricular function measured. When multivariate analysis was performed, none of these trials showed that patency was an independent prognostic factor when left ventricular function was measured other than acutely.
The Western Washington Trial showed that 1-year survival was related to infarct artery patency on univari- The Western Washington intravenous rt-PA trial showed left ventricular function to be the most important prognostic factor at 1-year follow-up, and patency was not associated with outcome.'3 Also, 5-year follow-up of the Interuniversity study, which compared the combined interventions of intracoronary streptokinase, intravenous streptokinase, and angiography with control treatment, showed left ventricular function to be the most important prognostic factor and did not demonstrate additional importance of infarct artery patency. 5 In studies such as those by the TAMI group, most patients are discharged with a patent infarct artery because of the aggressive use of revascularization procedures. It is therefore perhaps not surprising that it has not been possible to demonstrate an independent longterm prognostic benefit of a patent infarct artery in these trials. 37 In the present study, patency was assessed at 4 weeks in several ways. Flow as assessed by the TIMI criteria added prognostic information but did not reach traditional statistical significance. This method of analysis does not relate flow to the amount of myocardium supplied. There is marked variation in humans in the amount of myocardium supplied by a coronary artery. In canine models of acute infarction, most of the variation (66%) in infarct size is due to variation in the area of myocardium at risk if a coronary occlusion is produced.38 Our scoring system, which relates both patency and the extent of myocardium supplied by an artery, was a better predictor of outcome than TIMI grading. If the ejection fraction was >50% and the occluded coronary artery was small, supplying <25% of the left ventricle, prognosis was not adversely affected. When the ejection fraction was <50%, however, an occluded infarct-related artery was prognostically important no matter how small the myocardial supply.
If thrombolytic therapy is administered early, the predominant beneficial effect may be preservation of left ventricular function, whereas if thrombolytic therapy is administered late, the predominant effect may be related to the hypothesized beneficial effects of infarct artery patency.'7-21 However, because of the small number of patients (23) randomized within 1 hour, when myocardial preservation would be expected to be greatest, we were unable to show that greater preservation of left ventricular function was the predominant beneficial effect in those treated early and patency in those treated late.
Long-term infarct artery patency may be beneficial for a number of reasons. Patency may result in a reduction in ventricular arrhythmias.20 In a study of 32 patients with left ventricular aneurysms, ventricular tachycardia was induced in 88% of patients treated with routine care at electrophysiological study and in only 8 (8%) given thrombolytic therapy. At 11-month followup, patients who received thrombolysis had no events, whereas 50% of the patients treated routinely either died or had ventricular tachycardia.20 Reperfusion decreases infarct expansion and remodeling of the infarct and noninfarct zones with less ventricular dilatation.17"18 Dilatation may be reduced by improved infarct healing17 or splinting by a rim of salvaged epicardium and blood in the coronary arteries and veins supporting the infarct zone and preventing infarct expansion. 39 Decreased left ventricular volumes may improve long-term prognosis.'4 Patency of the infarct-related artery may also provide capacity for collateral blood flow if a subsequent occlusion occurs in a different coronary artery territory.
Treadmill exercise duration was an independent prognostic factor for all thrombolytic patients as well as for the subgroup of patients with occluded infarctrelated arteries. Time to angina and development of chest pain were not prognostic factors. For patients with patent infarct-related arteries, long-term ,-blocker therapy was prognostically important.
It is possible that other known risk factors not assessed in this study might have added prognostic information to the factors we identified or might have modified their interaction. We did not assess inducible ischemia with thallium scanning or heart rate variability, nor did we perform electrophysiological studies. [40] [41] [42] We did, however, assess primary risk factors such as smoking, hypercholesterolemia, and hypertension. Failure to demonstrate the prognostic importance of these factors may be due to the relatively short follow-up and the fact that active attempts at risk factor modification were made in all patients.
Our data cannot be extrapolated to justify strategies such as angioplasty or coronary artery bypass surgery aimed at opening infarct-related arteries that remain blocked after thrombolytic therapy, but they indicate a need for randomized trials addressing this question. It is likely that such strategies would be of most value in patients with decreased left ventricular function.
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